Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers.
Lindström. L H LH; Ekman. R R; Walleus. H H; Widerlöv. E E
Key Findings
- People with schizophrenia or major depression have significantly lower CSF levels of DSIP compared to healthy controls.
- Female schizophrenic patients tended to have lower DSIP than male patients.
- DSIP levels were inversely related to sleep disturbance scores in depressed patients, suggesting less DSIP = poorer sleep.
- Neuroleptic (antipsychotic) treatment did not change CSF DSIP levels.
Practical Outcomes
- For biohackers, the data hint that low natural DSIP may be linked to sleep problems in mood disorders, but the study does not test DSIP supplementation. It provides modest support for exploring DSIP as a sleep aid, yet no dosing or safety guidance is offered, so the immediate actionable value is limited.
Summary
The study measured the natural amount of the sleep‑related peptide DSIP in the spinal fluid of healthy people and patients with schizophrenia or depression. Both patient groups had lower DSIP levels than healthy volunteers, and lower DSIP was linked to worse sleep scores in depressed patients. No effect of antipsychotic drugs on DSIP was seen.
Abstract
CSF levels of DSIP was measured in healthy volunteers and in hospitalized patients with schizophrenia or major depressive disorders. Both patient groups had significantly lower CSF levels of DSIP than the healthy volunteers. There was a tendency for lower CSF levels of DSIP in female compared to male schizophrenics. Neuroleptic treatment did not significantly affect those levels. The levels of DSIP in CSF tended to be inversely correlated to the sleep disturbancy scores in the depressed patients.
Study Information
pubmed
1985
1985-12-31T00:00:00.000Z
10.1016/0278-5846(85)90182-4
18
15